Fidaxomicin
Indication
Treatment of Clostridium difficile infections (CDI) also known as C. difficile-associated diarrhoea (CDAD) in adults
Amber level 0
Brand:
Dificlir
Nice TA:
Commissioning responsibility:
CCG
PbR excluded:
No
BNF chapter:
Infection
Background
Fidaxomicin should be initiated by a microbiologist or under microbiologist recommendation.
Fidaxomicin (Dificlir®) to be considered as an option for use following a first or second relapse. i.e. as second or third line therapy.
Fidaxomicin to also be considered for patients with severe CDI who are considered to be at high risk for recurrence as per the Public Health England Guidance. e.g. elderly patients with multiple comorbidities who are receiving concomitant antibiotics and those not responding to oral vancomycin.
Recommendation
LSCMMG Recommendation:
Amber level 0
Reason for decision:
Suitable for GP prescribing following recommendation/initiation by specialist
Supporting documents: